Xencor’s (XNCR) Buy Rating Reiterated at Truist Financial

Posted by Francis Steltz on Oct 1st, 2026

Truist Financial reissued their buy rating on shares of Xencor (NASDAQ:XNCR – Free Report) in a research note issued to investors on Monday,Benzinga reports. Truist Financial currently has a $29.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $27.00.

Other analysts also recently issued reports about the company. Cantor Fitzgerald increased their price target on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Royal Bank Of Canada upped their target price on Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their target price on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, September 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.00.

Read Our Latest Research Report on XNCR

Xencor Stock Down 0.2%

Shares of XNCR stock opened at $24.95 on Monday. Xencor has a fifty-two week low of $10.38 and a fifty-two week high of $30.61. The firm’s 50 day moving average price is $24.11 and its two-hundred day moving average price is $16.94. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -11.50 and a beta of 0.88.

Xencor (NASDAQ:XNCR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The business had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.41) EPS. On average, equities analysts forecast that Xencor will post -3.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Xencor during the second quarter worth approximately $219,785,000. Primecap Management Co. CA acquired a new position in Xencor during the 2nd quarter worth $163,919,000. BVF Inc. IL increased its position in shares of Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Xencor by 2.8% in the 4th quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock valued at $20,027,000 after purchasing an additional 35,088 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Xencor by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after buying an additional 45,599 shares during the last quarter.

About Xencor

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies.